Drugs / NECVAX-NEO1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05354323 | May 2022 → Dec 2025 overdue | — | NEC OncoImmunity AS | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06631092 | Nov 2024 → Dec 2027 expected | triple-negative breast carcinoma | NEC Bio B.V | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06631079 | Oct 2024 → Jul 2026 overdue | cancer | NEC Bio B.V | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NECVAX-NEO1 | “Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer” NCT06631092 ↗ |
| Modality | Vaccine | “Personalized patient-individual oral DNA vaccine” NCT05354323 ↗ |
| Route | Oral | “Oral Ty21a based T-cell vaccination” NCT05354323 ↗ |